About: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.56 (-3.81%)
RNAC NASDAQ Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc. share price
RNAC price activity
Last Price
$6.560
Change (24hr)
-0.26 USD (3.81%)
Volume
33.23K
Volume (4w avg)
-
Open
$6.85
Day Range
$6.50 - $6.86
Previous Close
$6.82
Last Trade
05 Nov, 3:58 pm GMT+0
Delayed
05 Nov, 3:58 pm GMT+0
RNAC price performance
Delayed
05 Nov, 3:58 pm GMT+0
RNAC details
RNAC Market Signals